ATP1A3-related disorder overlapping syndrome: a case report
Objective: The phenotypic spectrum in dystonic syndromes in ATP1A3-related disorders is wide. History of drug-refractory seizures, developemental delay, incoordination, dysarthria and dysphagia and movement disorders…Tetradystonics patients may be misdiagnosed?
Objective: Present a case of movement disorder that genetic panel hasn’t tracked in the screening, and it’s stabilization with L-carnitine. Background: isobutyryl-CoA dehydrogenase deficiency is…Efficacy and safety of deutetrabenazine in children and adolescents with dyskinesia in cerebral palsy
Objective: To evaluate the efficacy and safety of deutetrabenazine (DTBZ) in children and adolescents with dyskinesia in cerebral palsy (DCP). Background: There are currently no…Neuroimaging and correlation with functional status in children with cerebral palsy
Objective: To analyse the neuroimaging findings and to establish a correlation between clinical features and magnetic resonance imaging (MRI) patterns in children with cerebral palsy…Lack of immunogenicity of incobotulinumtoxinA in pediatrics: A pooled analysis
Objective: To present pooled data analyses of the immunogenicity of incobotulinumtoxinA (INCO) in pediatrics. Background: BotulinumtoxinA (BoNT-A) is used to treat several chronic pediatric conditions,…Safety of incobotulinumtoxinA in pediatrics: A pooled analysis
Objective: To present analyses of pooled data on the safety of incobotulinumtoxinA (INCO) in pediatrics Background: BotulinumtoxinA (BoNT-A) is used to treat several conditions affecting…Absence of neutralizing antibody formation during incobotulinumtoxinA treatment of spasticity in botulinum toxin-naïve children with cerebral palsy: pooled analysis of Phase 3 studies
Objective: To investigate neutralizing antibody (NAb) formation in three large Phase 3 studies with incobotulinumtoxinA, a botulinum neurotoxin type A (BoNT-A) with no complexing proteins,…Efficacy and safety of incobotulinumtoxinA for upper- or combined upper- and lower-limb spasticity in children/adolescents with cerebral palsy: the XARA study
Objective: To assess the efficacy/safety of incobotulinumtoxinA for upper- and combined upper-/lower-limb spasticity in ambulant and non-ambulant children/adolescents with cerebral palsy (CP). Background: Spastic CP…Improvement of spasticity-related pain with incobotulinumtoxinA treatment in children/adolescents with cerebral palsy: pooled analysis of Phase 3 studies
Objective: To assess the effect of incobotulinumtoxinA on spasticity-related pain (SRP) using pooled data from three large Phase 3 pediatric studies. Background: In children/adolescents with…Pooled efficacy and safety analysis of incobotulinumtoxinA for upper- and lower-limb spasticity in children with severe cerebral palsy (GMFCS levels IV–V)
Objective: To assess the efficacy and safety of incobotulinumtoxinA for lower-limb (LL) and upper-limb (UL) spasticity in children and adolescents with cerebral palsy (CP) and…
- 1
- 2
- 3
- 4
- Next Page »